Formic Acid

Formic Acid

SCHEMBL30738085

Clc1ccc(Nc2nccc3ccoc23)cn1.O=CO

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ASIC3 Q9UHC3 1/20 0.45
TNF P01375 1/20 0.42
PIK3CA P42336 1/20 0.38
GRM4 Q14833 1/20 0.38
JAK2 O60674 6/20 0.35
JAK1 P23458 6/20 0.35
KCNQ3 O43525 8/20 0.35
KCNQ2 O43526 8/20 0.35
KCNQ1 P51787 6/20 0.35
KCNE1 P15382 5/20 0.35
BACE1 P56817 1/20 0.34
PIK3CG P48736 1/20 0.33
TRPA1 O75762 1/20 0.33
SCN5A Q14524 1/20 0.33
GRM5 P41594 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL26928765 1.00 ASIC3 (0.45) ASIC3TNFPIK3CAGRM4JAK2
SCHEMBL30737893 0.92 ASIC3 (0.51) ASIC3TNFPIK3CAGRM4JAK2
SCHEMBL26928464 0.92 ASIC3 (0.51) ASIC3TNFPIK3CAGRM4JAK2
Formic Acid SCHEMBL30738123 0.80 FADS1 (0.53) TNFPIK3CAGRM4JAK2JAK1
Formic Acid SCHEMBL26928810 0.80 FADS1 (0.53) TNFPIK3CAGRM4JAK2JAK1
Formic Acid SCHEMBL27179281 0.78 GRM4 (0.52) TNFPIK3CAGRM4KCNQ3KCNQ2
Formic Acid SCHEMBL26928762 0.76 KCNQ3 (0.42) TNFPIK3CAGRM4KCNQ3KCNQ2
Formic Acid SCHEMBL26928748 0.75 TNF (0.45) TNFPIK3CAGRM4KCNQ3KCNQ2
Formic Acid SCHEMBL30738171 0.72 CSNK2A2 (0.40) TNFPIK3CAGRM4KCNQ3KCNQ2
Formic Acid SCHEMBL26928873 0.72 CSNK2A2 (0.40) TNFPIK3CAGRM4KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4536356-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS Xenon Pharmaceuticals Inc. (CA) 2025-04-16 EP disclosed
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2024-03-28 US disclosed
WO-2023239729-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS XENON PHARMACEUTICALS INC. (CA) 2023-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101531-A1 PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNA1, KCNB1, KCNB2 ASIC3 1055/4885TNF 4805/4885PIK3CA 1559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.